Trials / Unknown
UnknownNCT04621669
Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride
A Multi-center, Open-lable, Fixed-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of SHR3680 With Pgoxin (P-gp Substrates), Rosuvastatin Calcium (BCRP and OATP1B1/1B3 Substrates) and Metformin Hydrochloride (MATE1/2-K Substrates) in Prostate Cancer Patients
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of digoxin, Rosuvastatin calcium and metformin hydrochloride
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR3680 | 240 mg |
| DRUG | digoxin | 0.25 mg |
| DRUG | Rosuvastatin calcium | 10 mg |
| DRUG | metformin hydrochloride | 500 mg |
Timeline
- Start date
- 2020-11-19
- Primary completion
- 2021-05-12
- Completion
- 2021-07-05
- First posted
- 2020-11-09
- Last updated
- 2020-11-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04621669. Inclusion in this directory is not an endorsement.